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Background: The Transient Receptor Potential Melastatin member 4 (TRPM4) gene
encodes a calcium-activated non-selective cation channel expressed in several tissues.
Mutations in TRPM4 have been reported in patientswith different types of cardiac conduction
defects. It is also linked to immune response and cancers, but the associated molecular
mechanisms are still unclear. Thus far, 9-phenanthrol is the most common pharmacological
compound used to investigate TRPM4 function. We recently identified two promising
aryloxyacyl-anthranilic acid compounds (abbreviated CBA and NBA) inhibiting TRPM4.
However, all aforementioned compounds were screened using assays expressing
human TRPM4, whereas the efficacy of mouse TRPM4 has not been assessed. Mouse
models are essential to investigate ion channel physiology and chemical compound efficacy.
Aim: In this study, we performed comparative electrophysiology experiments to assess
the effect of these TRPM4 inhibitors on human and mouse TRPM4 channels
heterologously expressed in TsA-201 cells.
Methods and Results: We identified striking species-dependent differences in TRPM4
responses. NBA inhibited both human and mouse TRPM4 currents when applied
intracellularly and extracellularly using excised membrane patches. CBA inhibited
human TRPM4, both intracellularly and extracellularly. Unexpectedly, the application of
CBA had no inhibiting effect on mouse TRPM4 current when perfused on the extracellular
side. Instead, its increased mouse TRPM4 current at negative holding potentials. In
addition, CBA on the intracellular side altered the outward rectification component of
the mouse TRPM4 current. Application of 9-phenanthrol, both intracellularly and
extracellularly, inhibited human TRPM4. For mouse TRPM4, 9-phenanthrol perfusion
led to opposite effects depending on the site of application. With intracellular 9-
phenanthrol, we observed a tendency towards potentiation of mouse TRPM4 outward
current at positive holding potentials.
Conclusion: Altogether, these results suggest that pharmacological compounds
screened using “humanised assays” should be extensively characterised before
application in vivo mouse models.
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INTRODUCTION
Transient Receptor Potential (TRP) ion channels constitute a
superfamily of cationic channels permeable to Na+, Ca2+, and/or
Mg2+ (Nikolaev et al., 2019). By contributing to intracellular Ca2+
signalling (Tsagareli and Nozadze, 2020; Wang et al., 2020), they are
critically involved in various calcium-dependent cell functions. The
TRP family member TRPM4 has received much attention due to its
implication in many physiological functions such as cardiac activity
(Guinamard and Bois, 2007; Liu et al., 2010; Stallmeyer et al., 2012;
Guinamard et al., 2015; Piao et al., 2015), immune response (Launay
et al., 2004; Barbet et al., 2008; Hemmer et al., 2015), cancer (Sagredo
et al., 2018), arterial constriction (Earley et al., 2004), insulin
secretion (Cheng et al., 2007), and cell death (Simard et al.,
2012). TRPM4 is expressed in many organs, including the heart,
kidney, and brain (Reading and Brayden, 2007; Abriel et al., 2012;
Simard et al., 2013; Flannery et al., 2015; Mehta et al., 2015), and is
upregulated in specific cancer cells, rendering it a promising
therapeutic target (Berg et al., 2016; Gao and Liao, 2019; Sagredo
et al., 2019). Unlike most other TRP channels, which are calcium-
permeable, TRPM4 is only permeable to monovalent cations, while
intracellular calcium activates the channel in a voltage-dependent
manner. Its activation leads to plasma membrane depolarisation,
thereby regulating calcium homeostasis by decreasing the driving
force for calcium to enter the cell through calcium-permeable
channels (Launay et al., 2002; Nilius et al., 2004).
Many pre-clinical in vivo pharmacological studies are
performed in mouse models, but TRPM4-inhibiting
compounds are generally screened using heterologous systems
expressing the human TRPM4 channel. It is highly relevant to
study the effect of TRPM4-inhibiting compounds on human and
mouse TRPM4, as TRP channel orthologues from different
species may show remarkable functional differences:
Mammalian TRPV1, for instance, is activated by capsaicin,
whereas chicken trpv1 is entirely insensitive to it (Jordt and
Julius, 2002; Chu et al., 2020). Another example is the species-
dependent effect of CMP1, a thioaminal-containing compound
that activates rat TRPA1 but blocks human TRPA1 (Chen et al.,
2008). Similarly, caffeine activates mouse TRPA1, but suppresses
human TRPA1 (Nagatomo and Kubo, 2008). Other studies have
shown species-specific effects of protein modulators and
temperature on TRPM8 (Hilton et al., 2018) and TRPV1
(Papakosta et al., 2011), respectively.
In this study, we characterised the specificity and potency of
three TRPM4 inhibitors (Figure 1A): 9-phenanthrol, 4-chloro-2-
[2-(2-chloro-phenoxy)-acetylamino]-benzoic acid (CBA,
formerly named compound 5 in (Ozhathil et al., 2018)), and
4-chloro-2-(2-(naphthalene-1-yloxy) acetamido) benzoic acid
(NBA, formerly named compound 6 in (Ozhathil et al.,
2018)). Compound 9-phenanthrol has been widely used to
inhibit TRPM4 in functional assays. However, its poor
selectivity limits the validity of its use in animal models or
primary cell lines (Burris et al., 2015; Ma et al., 2017). It is
particularly problematic that past studies on TRPM4 have based
their conclusions on patch-clamp assays that used this inhibitor
despite its low potency and low specificity. CBA and NBA have
been developed by our group and more potently inhibit TRPM4
than 9-phenantrol does (Ozhathil et al., 2018). Since these
pharmacological compounds were discovered in a screening
assay based on cell lines expressing human TRPM4, however,
it was crucial to study their effect on mouse TRPM4.
Using the patch-clamp technique in cells expressing human or
mouse TRPM4, we characterised the differences in specificity and
potency of CBA, NBA, and 9-phenanthrol. We observed that
CBA inhibits human TRPM4 but not mouse TRPM4, while NBA
inhibits mouse and human TRPM4. Finally, 9-phenanthrol
inhibits human TRPM4 and affects mouse TRPM4 currents
differently depending on whether it is applied on the
intracellular or extracellular side.
MATERIALS AND METHODS
Cell Culture
Transformed human embryonal kidney (TsA-201) cells stably
overexpressing either mouse TRPM4, human TRPM4, or empty
vector (pCDNA3.1 Zeo (+)) were generated using zeocin as a
selection antibiotic. The cells were cultured in Dulbecco’s
Modified Eagle’s medium (DMEM, #41965039) (Invitrogen,
Zug, Switzerland) supplemented with 10% FBS, 4 mM
glutamine, penicillin/streptomycin (50 U/ml), and Zeocin® 1/
500 (Invitrogen cat# R250-01). They were kept at 37°C with
5% CO2 in a humidified atmosphere incubator.
Western Blot
To detect TRPM4 protein expression, whole-cell lysates were
prepared by lysing cells in lysis buffer [50 mM HEPES pH 7.4;
150 mM NaCl; 1.5 mM MgCl2, 1 mM EGTA pH 8.0; 10%
glycerol; 1% Triton X-100; complete protease inhibitor cocktail
(Roche, Mannheim, Germany)] for 1 h at 4°C. Cell lysates were
centrifuged for 15 min at 16,000 × g at 4°C, pellets discarded, and
protein concentration of the supernatant was evaluated using the
Bradford assay. Sixty μg of each protein sample was run on 9%
polyacrylamide gels and transferred to a nitrocellulose membrane
with the Turbo Blotdry blot system (Biorad, Hercules, CA,
United States). After transfer, membranes were blocked with
0.1% BSA in PBS and incubated with rabbit primary anti-TRPM4
antibodies (epitope: VGPEKEQSWIPKIFRKKVC) (generated by
Pineda, Berlin, Germany) diluted 1:750 in PBS/Tween using the
SNAP i.d. system (Millipore, Billerica, MA, United States),
followed by incubation with secondary antibodies (IRDye
800CW 1:1,000 in PBS/Tween, LI-COR Biosciences, Lincoln,
NE, United States). Membranes were scanned using the LiCor
Odyssey Infrared imaging system (LI-COR Biosciences).
Compounds Tested
Nine-phenanthrol (9-Phe) was obtained from Sigma-Aldrich
(Buchs SG, Switzerland). Compounds CBA, NBA, and the
other anthranilic acid amides (Figure 7) were synthesised as
previously described (Ozhathil et al., 2018).
Inside-Out Patch Clamp
Electrophysiological recordings were performed in the inside-
out patch-clamp configuration with patch pipettes (1 and 2 μm
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tip opening) pulled from 1.5 mm borosilicate glass capillaries
(Zeitz-Instruments GmbH, München, Germany) using
micropipette puller P 97 (Sutter Instruments, Novato, CA,
United States). The tips were polished to have a pipette
resistance of 2–4 MΩ in the bath solution. The pipette
solution contained (in mM) 150 NaCl, 10 HEPES, and 2
CaCl2 (pH 7.4 with NaOH). The bath solution contained (in
mM) 150 NaCl, 10 HEPES, 2 HEDTA (pH 7.4 with NaOH), and
no Ca2+. Solutions containing 300 μM Ca2+ were made by
adding the appropriate concentration of CaCl2 without buffer
to a solution containing (in mM) 150 NaCl, 10 HEPES (pH 7.4
with NaOH) as reported previously (Zhang et al., 2005). Bath
solution with 0 and 300 μMCa2+ concentrations were applied to
cells by a modified rapid solution exchanger (Perfusion Fast-
Step SF-77B; Warner Instruments Corp. CT, United States).
Membrane currents were recorded with a Multiclamp 700B
amplifier (Molecular Devices, Sunnyvale CA, United States)
controlled by Clampex 10 via Digidata 1332A (Molecular
Devices, Sunnyvale, CA, United States). Data were low-pass
filtered at 5 kHz and sampled at 10 kHz. Experiments were
performed at room temperature (20–25°C). The holding
potential was 0 mV. For measuring steady-state currents, the
stimulation protocol consisted of two sweeps with a total
duration of 1,000 ms, the first sweep at −100 mV for 500 ms
and the second at +100 mV for 500 ms (Figure 2). The effect of
the compounds on TRPM4 current has been calculated by
averaging the last 100 ms of the second sweep at +100 mV.
The I-V relationships (IV curves) have been determined using
an I-V protocol from −100 mV to +100 mV for 500 ms with a
difference of 20 mV between each sweep (cf. Figure 6). The IV
curves have been normalised to the maximum current. No fit
was applied.
Application of the Compounds and ATP
After obtaining inside-out membrane patches, the presence of
TRPM4 in the patch membrane was confirmed by switching the
perfusion solution without calcium at the intracellular side of the
membrane to a solution containing 300 μM calcium, which
activates TRPM4 and triggers the current. Once the TRPM4
currents were activated and stabilised for intracellular compound
application, the perfusion solution containing 300 μM calcium
and either the compound or free adenosine triphosphate (ATP)
was applied. For extracellular application, the compounds were
added to the intracellular (pipette) solution.
FIGURE 1 | TRPM4 pharmacological compounds used in this study. (A) Structure of 9-phenanthrol (left), NBA (middle), and CBA (right). (B)Concentration-response curve
showing the cytotoxicity of 9-phenanthrol (black circles), CBA (red squares), NBA (blue triangles), and DMSO (grey plus symbols) (n  6 for each concentration).
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Cytotoxicity Test
Untransfected TsA-201 cells were seeded in a 96-wells plate at a
concentration of 10,000 cells per well with DMEM and incubated at
37°C and 5% CO2 in a humidified atmosphere incubator overnight.
After reaching 80–90% of cell confluence, the cells in the 96-well plate
were treatedwith different compound concentrations (0.5, 1, 2, 4, 10, 50,
FIGURE 2 | Validation of cell lines stably expressing TRPM4. (A) Expression of TRPM4 channels in stably transfected cell lines. (A1)Western blot showing TRPM4
expression as detected by anti-TRPM4 antibody from whole-cell extracts prepared from TsA-201 cells. (A2) functional expression of TRPM4 channels in the different
stable cell lines (n  9 to 10 for each condition). **p ≤ 0.01 and ***p ≤ 0.001. (B) Effect of free ATP on TRPM4 current. (B1), representative traces of TRPM4 current
activated by 300 μM calcium (black) and inhibited by 10 μM free ATP (blue) currents recorded from excised membrane patches (inside-out) (up and lower panels,
respectively, human andmouse TRPM4). (B2), the effect of free ATP on TRPM4 current. The values were fitted with the Hill equation to interpolate IC50 values of free ATP
(n  6 for each concentration).
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500, and 5,000 µM of CBA, NBA, and 9-phenanthrol) for 24 h. After
incubation, the cellswerewashed and incubated in 0.01% trypsin-EDTA
until the cellular layer was completely detached. Cells were centrifuged
down, and the pellet resuspended in 1ml PBS. Cells were then diluted in
1 part of 0.4% trypan blue and 1-part cell suspension. This mixture was
incubated for 3min at room temperature. Finally, the unstained (viable)
and stained (nonviable) cells were counted in the haemocytometer
(BRAND® counting chamber BLAUBRAND®, Wertheim, Germany).
Data Analyses and Statistics
Electrophysiology data were analysed using IGOR PRO 6
(WaveMetrics, Lake Oswego, United States), Normalized
FIGURE 3 | Species-specific effects of 9-phenanthrol on TRPM4 currents. Representative traces of TRPM4 currents recorded from excised membrane patches
(inside-out) from cells expressing human (A1 and B1 upper panels) and mouse (A1 and B1 lower panel) TRPM4. 30 μM 9-phenanthrol is added to the intracellular (A) or
extracellular (B) side (black traces: control and blue traces; treated). All TRPM4 currents were obtained after perfusion with 300 μM free calcium solutions. (A2 and B2)
Human TRPM4 (circle) and mouse TRPM4 (square) average current amplitudes at the end of voltage step to +100 mV with (blue) or without (black) 9-phenanthrol.
Voltage protocol is given at the top of panel A (n  6). **p ≤ 0.01
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current percentage inhibition was calculated as follows ([activated
current at 300 μM calcium]—[activated current at 300 μM calcium
with compound]) * 100/[activated current at 300 µM calcium].
Concentration-response curves were fitted using the Hill equation
fit parameter of IGOR (NC  NCmax [Cmpd]nH/([Cmpd]nH +
EC50 nH)) where NC is normalized current [Cmpd] is compound
concentration and nH is the Hill coefficient. Data are presented as
mean ± SEM except for Figures 3 and 7, where the data have been
normalised to 100 for the current recorded in the presence of
300 µM calcium only. Statistically significant differences
conditions were determined using a non-parametric test with a
Mann-Whitney post-test. P-values ≤ 0.05; ≤0.01; ≤0.001 were
FIGURE 4 | NBA has similar effects on human and mouse TRPM4 currents. (A1 and B1) Representative traces of TRPM4 currents recorded from excised
membrane patches (inside-out). Human TRPM4 (A1, upper panel) and mouse TRPM4 (A1, lower panel) currents in the presence (blue) or absence of 10 μMNBA (black)
in the pipette solution (extracellular application). Human (B1, upper panel) and mouse (B1, lower panel) TRPM4 currents in the presence (blue) or absence (black) of
10 μM NBA in the bath solution (intracellular application). All TRPM4 currents were obtained after perfusion with 300 μM free calcium solution. (A2 and B2)
Concentration-response curves of human (red circles) and mouse (black triangles) TRPM4 for NBA either in pipette solution (extracellular application) (B1) or in the bath
solution (intracellular application) (B2) (n  6 for each concentration). Data were fitted with a Hill equation to interpolate the IC50.
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considered as statistically significant and marked with *, **, and ***
respectively in the different figure panels.
RESULTS
Nine-Phenanthrol is More Cytotoxic Than
CBA and NBA
First, we tested the cytotoxicity of the three selected TRPM4
compounds (Figure 1A). The calculated EC50, corresponding to the
concentration of the inhibitor required to induce 50% of cell death, was
15- to 25-fold lower for 9-phenanthrol (EC50 ∼ 20 μM) than for NBA
(EC50∼ 332 μM) andCBA (EC50∼ 545 μM), respectively (Figure 1B).
These observations illustrate that the two new compounds CBA and
NBA, are less cytotoxic than 9-phenanthrol.
Characterisation of TsA-201 Cell Lines
Stably Overexpressing Either Human or
Mouse Transient Receptor Potential
Melastatin Member 4
To characterise the TsA-201 cell lines stably overexpressing either
wild-type human or mouse TRPM4 generated for this study, we first
tested the TRPM4 protein expression by western blot (Figure 2A1).
Using an antibody recognising TRPM4 from both species, a robust
expression of TRPM4was observed in these modified cells compared
to the cells transfected with an empty vector (Figure 2A1). To
investigate if these cell lines express functional channels, we
performed inside-out patch-clamp experiments to first record the
calcium-sensitive current (Figure 2A2) and second to investigate the
well-known TRPM4 inhibitory effect of free ATP on TRPM4
currents (Figures 2B1,B2). As expected, robust TRPM4 currents
were observed in TsA-201 cell lines stably expressing either human or
mouse TRPM4 channels compared to untransfected cells, also known
to expressed endogenous TRPM4 channels (Figure 2A2). This
current decreased after intracellular application of free ATP
(Figures 2B1,B2). On the concentration-response curves depicted
in Figure 3B2, the intracellular ATP IC50 for both types of channels
was 0.8 μM for human TRPM4 and 1.4 μM for mouse TRPM4
(Figure 2B2). Altogether, these results confirm that both cell lines
expressed functional human or mouse TRPM4 wild-type channels
and can be used for further investigations.
Nine-Phenanthrol Inhibits Human Transient
Receptor Potential Melastatin Member 4
Current and Upregulates Mouse Transient
Receptor Potential Melastatin Member 4
Current When Applied Intracellularly
Knowing that lipophilicity tools have predicted that 9-
phenanthrol may cross the plasma membrane, we decided to
record mouse and human TRPM4 currents in the presence of the
three compounds (9-phenanthrol, CBA, and NBA) either applied
at the intracellular side (bath solution) or the extracellular side
(pipette solution).
First, we tested the effects of 9-phenanthrol on human andmouse
TRPM4 channels. Thirty μM 9-phenanthrol, corresponding to the
previously determined IC50 (Figure 1B), was applied using a
perfusion solution containing 300 μM calcium (Ozhathil et al.,
2018). Nine-phenanthrol inhibited human TRPM4 sodium
current with a similar efficacy independently of the application
side (extracellular or intracellular) (Figures 3A1,B1,A2,B2).
Unexpectedly, while extracellular (pipette solution) 9-phenanthrol
decreased the mouse TRPM4 current, it increased the current when
applied intracellularly (Figures 3A1,B1,A2,B2). This increase was
observed only in the presence of 300 μM calcium, suggesting that 9-
phenanthrol acts as a potentiator rather than as an activator of the
mouse TRPM4 current (Figure 8A). Moreover, this effect was more
pronounced with low concentrations (0.1 μM) of 9-phenanthrol
than with higher concentrations (Figure 8B). When applying
100 μM 9-phenanthrol, the observed potentiator effect was
smaller than in the presence of 0.1 µM 9-phenanthrol (Figure
8B). Altogether, these data illustrate that the effects mediated by
9-phenanthrol depend on the excised membrane patch application
side and are species-specific.
NBA Decreases Both Human Transient
Receptor Potential Melastatin Member 4
and Mouse Transient Receptor Potential
Melastatin Member 4 Currents
Analogous to our experiments with 9-phenanthrol, we performed
patch-clamp recordings using the compound NBA. We observed
that 10 μM NBA inhibited both human and mouse TRPM4
current independent of the side of the application (Figures
4A1,A2,B1,B2). The concentration-response curve for NBA
revealed a sigmoid curve for both human and mouse TRPM4
currents (Figures 4A2,B2). Fitting the data with the Hill equation
revealed that the IC50s of NBA are 0.187 and 0.119 μM for human
and mouse TRPM4, respectively, when applied intracellularly
(Figure 4B2). The IC50s of extracellular NBA were 0.125 and
0.215 μM with human and mouse TRPM4, respectively (Figure
4A2). Taken together, these data suggest that NBA does not
discriminate between human and mouse TRPM4 channels and
inhibits the TRPM4 current when applied to either side of the
membrane.
CBA Decreases Only Human, not Mouse,
Transient Receptor Potential Melastatin
Member 4 Currents
Next, we assessed the effects of CBA on human and mouse
TRPM4 currents. The application of 10 μM CBA decreased the
human TRPM4 currents independent of the side of the
application (Figures 5A1,A2,B1,5B2). The IC50s were 0.7 μM
(extracellular application/pipette solution) and 0.8 μM
(intracellular application) (Figures 5A2,B2). However, in
membrane patches expressing mouse TRPM4 channels,
neither the extracellular nor the intracellular application of
CBA altered the TRPM4 currents (Figures 5A1,A2,B1,B2).
Surprisingly, when CBA was applied intracellularly, a small
but significant effect on mouse TRPM4 current was observed
at positive voltages (+100 mV), while at negative membrane
voltages (−100 mV), the current was significantly higher
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(Figure 5B1; Figure 6). In addition, the percentage of
inactivation at -100 mV and activation at +100 mV were
significantly decreased after CBA application (Table 1). Based
on this observation, we recorded a current-voltage relationship
(I-V) protocol to quantify the effect of intracellular CBA
application on mouse TRPM4 current at different membrane
voltages (Figure 6). As previously observed in Figure 5, CBA
increased the inward current at negative membrane voltages
(Figure 6) but only slightly altered the amplitude of the
outward current at positives membrane voltages (Figure 6).
Doing so, CBA led to a linearisation of the I-V relationship
removing the rectification features. Altogether, these results
FIGURE 5 | CBA blocks TRPM4 in a species-specific manner. (A1 and B1) Representative traces of TRPM4 currents recorded from excised membrane patches
(inside-out). Human TRPM4 (A1, upper panel) and mouse TRPM4 (A2, lower panel) currents in the presence (blue) or absence (black) of 10 μM CBA in the pipette
solution (extracellular application). Human (B1, upper panel) and mouse (B1, lower panel) TRPM4 currents in the presence (blue) or absence (black) of 10 μMCBA in the
bath solution (intracellular application). All TRPM4 currents were obtained after perfusion with 300 μMof free calcium solution. (A2 andB2) Concentration-response
curves on human (red circles) and mouse (black squares) TRPM4 currents for CBA. CBA was applied in the pipette solution (A2, extracellular application) or in the bath
solution (B2, intracellular application) (n6 for each concentration). Data were fitted with a Hill equation to interpolate the IC50.
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illustrate that the effect of CBA is species-specific, and CBA alters
the inward current of mouse TRPM4.
NBA- and CBA-Derived Compounds Have
Similar, but not the Same, Effects
To finally investigate if the effects observed could depend on
further chemical structures, additional patch-clamp experiments
were performed using compounds closely related to TRPM4
inhibitors CBA and NBA structures. They were selected based
on a Structure-Activity Relationship (SAR) rationale
(Ozhathil et al., 2018). The CBA-derived compound used
was 4-chloro-2-(2-((4-chloro-2-methylphenoxy) propanamido)
benzoic acid (CBA-d1) (Figure 7A1). The selected NBA-derived
compounds were 4-chloro-2-(2-((4- chloronaphthalen-1-yl) oxy)
acetamido) benzoic acid (NBA-d1) and 4-chloro-2-(2-((5,6,7,8-
tetrahydronaphthalen-1-yl) oxy) acetamido) benzoic acid (NBA-
d2) (Figures 7B1,C1). Interestingly, similarly to CBA, CBA-d1 did
not decrease the mouse TRPM4 currents when applied
intracellularly (Figures 7A1,A2). Contrary to CBA-d1, NBA-d1
and NBA-d2 could inhibit mouse TRPM4 currents, as also
observed with NBA compounds (Figures 7B1,B2,C1,C2).
Altogether, these results suggest that while some structurally
related compounds behave similarly to the original one (NBA-
d1 and NBA-d2 compared to NBA), some of them may have
slightly different effects (CBA-d1 and CBA).
DISCUSSION
In this study, we assessed the species-specific effects of
inhibitors of the calcium-activated non-selective
monovalent ion channel TRPM4. Despite the relevance of
TRPM4 for a wide range of physiological and pathological
processes in different tissues, its roles remain not well
understood. Identifying TRPM4 compounds that reliably
block TRPM4 current in humans and mouse models is crucial
to unravel the functions of TRPM4 and investigate it as a potential
therapeutic target. We characterised the effect and species
selectivity of three different TRPM4 small molecule inhibitors:
9-phenanthrol, NBA, and CBA. Further, we investigated three
CBA and NBA derivatives. Nine-phenanthrol remains a widely
used reference compound in studies to decipher the role of TRPM4
in mouse models. Although lipophilic prediction tools have
suggested the capability of 9-phenanthrol to cross the plasma
membrane, none of the studies published so far had
investigated its effect when specifically applied on the
intracellular side of the mouse TRPM4 channel using the inside
out patch-clamp configuration. Here, we show for the first time
FIGURE 6 | Effects of CBA onmouse TRPM4 current. Left panel shows raw traces of mouse TRPM4 currents recorded using the step protocol depicted at the top
of the figure, with (black) or without (red) 5 μM CBA in the extracellular bath (intracellular application). Right panel shows IV curves, representing the average current
amplitude at the end of each voltage step when the TRPM4 current was activated using 300 μM free calcium solution (black) and treated with 5 μM CBA (red) (n  8).
**p ≤ 0.01.
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that 9-phenanthrol inhibits mouse TRPM4 when applied on the
extracellular part of the patch membrane, but its application on the
inner membrane side leads to an evident potentiation of mouse
TRPM4 current. Moreover, as suggested in Figure 8, the
application of high concentrations of 9-phenantrol at the
extracellular side of the cell may lead to a reduced-inhibition
efficiency on TRPM4 current. It remains unclear whether 9-
phenanthrol has a direct effect on mouse TRPM4 or whether
the observed increase in current is mediated by a second
messenger such as Mg-ATP or phosphatidylinositol-4,5-
bisphosphate, which are known to restore the
desensitisation of TRPM4 current (Zhang et al., 2005).
Further experiments are required to address this question.
Considering that 9-phenanthrol may cross the plasma
membrane altogether, these observations raised the question
of the global effect on the TRPM4 current of 9-phenanthrol
would be when applied either in a mouse model or in cultured
murine cells.
Interestingly, the potentiating effect of 9-phenanthrol when
applied intracellularly to mouse TRPM4 was blunted at
relatively high concentrations (Figure 8). Although more
experiments are required to decipher the molecular
mechanisms behind these observations, it can be proposed
that 9-phenanthrol, due to its lipophilicity, when applied at a
high concentration at the intracellular part of the cell, can
partly cross the lipid bilayer reaching the extracellular side of
the cell where it acts as an inhibitor. Conversely, 9-
phenanthrol applied to the outside surface of cells may also
cross the plasma membrane and cause a potentiating effect at
the intracellular-facing surface. Based on these considerations,
published studies that used 9-phenanthrol should be
interpreted with caution.
Considering that 1) the IC50 to block TRPM4 is much
higher for 9-phenanthrol than for NBA and CBA, 2) 9-
phenanthrol partially block other ion channels (Abriel
et al., 2012), and 3) its cytotoxicity is higher than NBA
and CBA, our results strongly suggest that 9-phenanthrol
is a suboptimal tool to dissect the TRPM4 physiological role
in mice. It is therefore recommended to perform future
experiments on mouse TRPM4 with NBA instead of 9-
phenanthrol. CBA has already been used in previous
publications using cell lines expressing TRPM4 (Bianchi
et al., 2018; Borgstrom et al., 2020). This compound is
more potent and more specific than 9-phenanthrol on
human TRPM4; indeed, CBA did not inhibit TRPV1,
TRPV3, TRPV6, TRPM5, TRPM7, or TRPM8 (Ozhathil
et al., 2018). Thus, CBA seems to be a promising inhibitor
of human TRPM4, which is especially interesting for the
cancer research field, where over-expression of human
TRPM4 correlates with higher malignancy (Kappel et al.,
2019; Borgstrom et al., 2020). CBA, however, does not inhibit
the mouse TRPM4 current (Figure 5) and significantly
decrease the activation and deactivation of mouse TRPM4
currents when applied intracellularly (Table 1). A possible
explanation for this species-specific effect may lie in the 20%
non-homology between mouse and human TRPM4
sequences. Generating chimeric constructs of mouse and
human TRPM4 channels to address this hypothesis will be
an important direction of study in the future. Moreover,
cryo-EM structures of these channels in the absence or
presence of NBA and CBA may provide important
information concerning their TRPM4-binding site(s).
Interestingly and unexpectedly, CBA alters biophysical
features of the mouse TRPM4 (outward and inward
currents) (Figures 5, 6B1), suggesting different
mechanisms of action of CBA on the mouse and human
TRPM4, the latter being entirely inhibited by CBA. The
site(s) of CBA action on the mouse and human TRPM4 is/
are not yet elucidated. The structure-function relationship
explaining these observations thus remains unknown. CBA-
derived compounds inhibit neither inward nor outward
mouse TRPM4 currents, suggesting that the differences in
their structure may affect the biophysical properties of the
channel differently. Taken together, our results suggest that
CBA should only be used to study functional properties of
human TRPM4 and avoided in mouse models.
Finally, NBA and the structurally related compounds
efficiently inhibit both mouse and human TRPM4 channels
(Figures 4, 7). NBA is, therefore, a novel and promising tool
compound to study the role of TRPM4 in both humans and mice.
Nonetheless, its site(s) of action still need(s) to be explored. We
propose that characterising the channel properties of TRPM4 in
diverse animal species and identifying the molecular
determinants of TRPM4 pharmacological compounds will
provide a foundation to develop new drugs to target TRPM4.
To better characterise these compounds, it will be interesting to
perform similar experiments in human in vitro models using
either primary (native) cells such as human cardiomyocytes or
induced pluripotent stem cell-derived cardiomyocytes. Lastly,
both CBA and NBA should be tested in TRPM4 orthologs
from other species.
The previous characterisation by TRPM4-mediated Na+
influx assays and electrophysiology experiments has shown
that NBA is about 4–9 times more potent than CBA (Ozhathil
TABLE 1 | Percentage of variation of mouse TRPM4 currents during the first 400 ms of the pulse at −100 mV and the first 400 ms of the pulse at +100 mV (see protocol
Figure 3B1) with and without intracellular application of CBA at 10 µM (n  6 for each parameter). **p ≤ 0.01 and ***p ≤ 0.001.
Without intracellular CBA With intracellular CBA
(10 µM)
Decrease in percent of mouse TRPM4 current at −100 mV during the first 400 ms −22 ± 3% (n  11) −10 ± 1% (n  11) ***
Increase in percent of mouse TRPM4 current at +100 mV during the first 400 ms 26 ± 6% (n  11) 10 ± 4% (n  11) **
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et al., 2018). Unfortunately, without a precise cryo-EM
structure of the TRPM4 (Guo et al., 2017; Winkler et al.,
2017) channel or other experimental evidence about the
binding sites of CBA and NBA, it is challenging to
explain why NBA is more potent than CBA. We can only
speculate that the additional ring of the naphthalene
substituent of NBA can form attractive interactions with
a putative hydrophobic pocket of TRPM4, which the smaller
FIGURE 7 | Effect of CBA- and NBA-derived compounds on mouse TRPM4 current. Chemical structures of pharmacological compounds derived from NBA and
CBA (A1, B1, and C1; top panels). TRPM4 currents with 10 μM of either CBA-d1, NBA-d1, or NBA-d2 compounds. Mouse TRPM4 currents in the presence (blue) or
absence (black) of 10 μM of CBA-d1 (A1 and A2), NBA-d1 (B1 and B2), and NBA-d2 (C1 and C2) in the bath solution (extracellular application). All currents were
obtained after perfusion with 300 μM free calcium solution. (A2, B2, and C2) Average current amplitudes at the end of the voltage step to +100 mV. n ≥ 6 for all
conditions. *p ≤ 0.05.
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2-chlorophenyl ring of CBA cannot, or only to a much
smaller degree. Molecular docking of CBA and NBA into
human and mouse TRPM4 could suggest potential binding
sites that need to be corroborated by follow-up mutagenesis
studies.
Overall, the findings of the present study suggest that new
compounds should be carefully characterised before used as
tool compounds in animal models to avoid misinterpretation
of the results. Based on our work, NBA is a promising tool
compound to study the role of the TRPM4 channel in normal
physiology and under pathological conditions. Unfortunately,
the other compound, CBA, seems to be only interesting for
experiments using human TRPM4 (Ozhathil et al., 2018).
Finally, the TRPM4 inhibitor 9-phenanthrol, which has
FIGURE 8 |Nine-phenanthrol increases the mouse TRPM4 current only in the presence of calcium. (A) Representative traces of mouse TRPM4 currents recorded
from excised membrane patches (inside-out) before and after application (intracellular application) of different solutions. Black trace: mouse TRPM4 current with a
calcium-free and 9-phenanthrol-free solution; red trace: calcium-free and 9-phenanthrol solution with 30 μM of 9-phenanthrol; blue trace: 300 μM calcium solution
without 9-phenanthrol; green trace: 300 μMcalcium and 30 μMof 9-phenanthrol solution (similar observations were done with three different cells (data not shown).
(B) Low concentrations of 9-phenanthrol potentiated more efficiently mouse TRPM4 currents compared to high concentrations. Normalised mouse TRPM4 currents
from six different inside-out patches show a stronger potentiation of the current after low (0.1 μM) 9-phenanthrol concentration application (extracellular application)
compared to a high (100 μM) concentration of this compound (n  6).
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been used for more than a decade to characterise TRPM4
function in different tissues, should be avoided as much as
possible in favour of the two new characterised compounds
NBA and CBA.
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